Needham Reiterates Buy on Neumora Therapeutics, Maintains $8 Price Target
Benzinga Newsdesk 7 months ago
NewsPrice TargetReiterationAnalyst Ratings
Needham analyst Ami Fadia reiterates Neumora Therapeutics (NASDAQ:NMRA) with a Buy and maintains $8 price target.
Needham analyst Ami Fadia reiterates Neumora Therapeutics (NASDAQ:NMRA) with a Buy and maintains $8 price target.